We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01130584
Recruitment Status : Completed
First Posted : May 26, 2010
Last Update Posted : December 11, 2013
Sponsor:
Information provided by:
National University Hospital, Singapore

Brief Summary:

The purpose of this study is to determine if pyruvate kinase M2 (PKM2) can be used as a biomarker in cancer.

Pyruvate kinase M2 is more elevated in malignant pleural fluid than in plasma, and may be a useful biomarker to distinguish between malignant and non-malignant causes of pleural effusion. In addition, pyruvate kinase M2 has also been found to be elevated in saliva in cancer patients compared to controls. Measuring pyruvate kinase M2 in saliva may be used to diagnose cancer or monitor the treatment progress of cancer.


Condition or disease Intervention/treatment
Cancer Other: Pyruvate kinase isoform M2

Study Type : Observational
Observational Model: Cohort
Time Perspective: Prospective
Study Start Date : April 2010
Primary Completion Date : April 2013
Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
Cancer patient Other: Pyruvate kinase isoform M2




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Any cancer patient
Criteria

Inclusion Criteria:

  • Any cancer patient with pleural effusion that is being drained through an indwelling chest-tube in an inpatient ward.

Exclusion Criteria:

  • Patient with a pleural effusion who does not have proven cancer or whose pleural effusion is not known to be malignant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01130584


Locations
Singapore
National University Hospital, Singapore
Singapore, Singapore
Sponsors and Collaborators
National University Hospital, Singapore